News
Enhertu improves progression-free survival in breast cancer trial
Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conjugate (ADC) ADC demonstrated superiority over trastuzumab emtansine (T-DM1).